Efficacy of the herbal medicine Unkei-to as an adjunctive treatment to hormone replacement therapy for postmenopausal women with depressive symptoms.

abstract：:Adjunctive use of methylphenidate, a central stimulant, has been considered as a potential therapeutic choice for patients with refractory unipolar depression, geriatric depression, bipolar depression, and depression secondary to a medical illness. We present a case of psychotic unipolar depression in which the patien...

journal_title：Clinical neuropharmacology

authors： Huang CC,Shiah IS,Chen HK,Mao WC,Yeh YW

更新日期：2008-07-01 00:00:00

abstract：:Tiagabine (TGB), a recently approved antiepileptic drug (AED), has a specific mechanism of action that is unique among AEDs. A potent AED with linear, predictable pharmacokineties, it inhibits gamma-aminobutyric acid (GABA) reuptake into neurons and glia. Tiagabine does not have any clinically relevant effects on hepa...

journal_title：Clinical neuropharmacology

authors： Schachter SC

更新日期：1999-11-01 00:00:00

abstract：:Several recent reports attest to zolpidem's strong potential for abuse, dependence, and severe withdrawal symptoms upon its discontinuation. We report, for the first time, on 1 case of heavy zolpidem abuse and dependence with severe withdrawal symptoms twice treated safely and successfully with pregabalin, a newer ant...

journal_title：Clinical neuropharmacology

authors： Oulis P,Nakkas G,Masdrakis VG

更新日期：2011-03-01 00:00:00

abstract：:In a randomized double-blind study, 20 parkinsonian patients (suffering from the disease for 2-18 years), chronically treated with levodopa (500-750 mg/day for 0.5-12 years), received terguride (1 mg b.i.d.) or placebo for 4 weeks. Growth hormone (GH), prolactin (PRL), thyroid-stimulating hormone (TSH), and insulin-li...

journal_title：Clinical neuropharmacology

authors： Martignoni E,Horowski R,Liuzzi A,Costa A,Dallabonzana D,Cozzi R,Attanasio R,Rainer E,Nappi G

更新日期：1996-02-01 00:00:00

abstract：:To evaluate two different dosage regimens for albendazole (7.5 mg/kg twice a day or 5.0 mg/kg three times a day), a study was performed in 10 patients with a diagnosis of parenchymal brain cysticercosis. Each patient received both regimens sequentially according to a randomized, crossover design. Blood and urine sampl...

journal_title：Clinical neuropharmacology

authors： Sánchez M,Suástegui R,González-Esquivel D,Sotelo J,Jung H

更新日期：1993-02-01 00:00:00

abstract：OBJECTIVE:There has been an increase in the European and North American schizophrenia literature discussing the high prevalence of metabolic syndrome induced by atypical antipsychotic agents. The aim of this article was to review available data on metabolic syndrome induced by atypical antipsychotic agents in patients ...

journal_title：Clinical neuropharmacology

authors： Bou Khalil R

更新日期：2012-05-01 00:00:00

abstract：:Bupropion hydrochloride (HCl) is an antidepressant that has many different biological targets, acting as both a norepinephrine-dopamine reuptake inhibitor as well as a nicotinic antagonist. This second-generation antidepressant is available in 3 bioequivalent formulations: immediate release, sustained release, and ext...

journal_title：Clinical neuropharmacology

authors： Schwitalla TA,Patel RA,Catalano G,Nirmalani-Gandhy A

更新日期：2019-11-01 00:00:00

abstract：BACKGROUND:Topiramate (TPM) is a fructose derivative, which was originally developed as an antiepileptic. In this context, movement disorders (MDs) are possible adverse events secondary to TPM. CASE REPORTS:Two patients (cases 1 and 2) developed myoclonus, and the other 2 had restless leg syndrome (RLS, cases 3 and 4)...

journal_title：Clinical neuropharmacology

authors： Rissardo JP,Caprara ALF

更新日期：2020-07-01 00:00:00

abstract：OBJECTIVES:Ponezumab is a humanized antiamyloid beta (Aβ) monoclonal antibody designed to treat Alzheimer disease (AD). METHODS:This randomized, double-blind, single-dose-escalation study evaluated the safety, pharmacokinetics, and pharmacodynamics of 0.1, 0.3, 1, 3, and 10 mg/kg ponezumab (n = 4, 4, 4, 6, and 8, resp...

journal_title：Clinical neuropharmacology

authors： Landen JW,Zhao Q,Cohen S,Borrie M,Woodward M,Billing CB Jr,Bales K,Alvey C,McCush F,Yang J,Kupiec JW,Bednar MM

更新日期：2013-01-01 00:00:00

abstract：:Tolcapone, a central and peripheral catechol O-methyltransferase (COMT) inhibitor, reduces the conversion of L-Dopa into 3-O-methyl-Dopa (3-OMD), thus leading to more stable and sustained L-Dopa plasma levels. This study was designed to evaluate the effects of acute and 6-week tolcapone administration on L-Dopa pharma...

journal_title：Clinical neuropharmacology

authors： Napolitano A,Del Dotto P,Petrozzi L,Dell'Agnello G,Bellini G,Gambaccini G,Bonuccelli U

更新日期：1999-01-01 00:00:00

abstract：:Cyclosporine A (CsA) neurotoxicity is an iatrogenic disease with significant morbidity and occasional mortality. We retrospectively reviewed the cases of CsA neurotoxicity among bone marrow transplant recipients at our institution, and summarized the current literature on the subject. The neurologic presentation is va...

journal_title：Clinical neuropharmacology

authors： Shah AK

更新日期：1999-03-01 00:00:00

abstract：:Therapeutic strategies in the treatment of dystonia consist primarily of pharmacologic, surgical, and supportive approaches. Many recent advances have been made in the treatment of dystonia with newer medications, availability of different botulinum toxins, and surgical procedures. However, these treatment modalities ...

journal_title：Clinical neuropharmacology

authors： Goldman JG,Comella CL

更新日期：2003-03-01 00:00:00

abstract：:The extensive use of the Unified Parkinson's Disease Rating Scale (UPDRS) has revealed low interrater reliability in some items and redundancy in others. In view of these shortcomings, we have structured a new scale that includes a zero-to three-point scale for each item in the evaluation of PD. The mental axis includ...

journal_title：Clinical neuropharmacology

authors： Rabey JM,Bass H,Bonuccelli U,Brooks D,Klotz P,Korczyn AD,Kraus P,Martinez-Martin P,Morrish P,Van Sauten W,Van Hilten B

更新日期：1997-08-01 00:00:00

abstract：:To investigate clinical aspects of the neutropenia induced by high-dose intravenous immunoglobulin therapy (IVIG) we performed serial hematology, including differentiation of white blood cells (WBC), before and after 22 instances of IVIG in 16 patients with neuroimmunologic disorders. WBC and neutrophils showed a sign...

journal_title：Clinical neuropharmacology

authors： Matsuda M,Hosoda W,Sekijima Y,Hoshi K,Hashimoto T,Itoh S,Ikeda S

更新日期：2003-11-01 00:00:00

abstract：:In nine patients with orthostatic hypotension due to multiple system atrophy, the effects of octreotide (100 micrograms s.c.), a somatostatin analogue, on blood pressure (BP), heart rate (HR), and norepinephrine (NE) plasma levels after 60 degrees head up tilt test were evaluated by a randomly controlled study. Octreo...

journal_title：Clinical neuropharmacology

authors： Bordet R,Benhadjali J,Destée A,Belabbas A,Libersa C

更新日期：1995-02-01 00:00:00

abstract：:This article outlines the reasons that detection of subtle changes in the cognitive system is difficult in geriatric assessment. A new assessment approach is introduced that examines cognitive patterns and facilitates the evaluation of subtle changes. ...

journal_title：Clinical neuropharmacology

authors： Poon LW

更新日期：1993-01-01 00:00:00

abstract：:A patient with melanoma and sporadic positive melanuria developed Parkinson's disease. Treatment with levodopa failed to modify tumoral progress. However, during chemotherapy with dacarbazine, the patient experienced a significant impairment to levodopa response. ...

journal_title：Clinical neuropharmacology

authors： Merello M,Esteguy M,Perazzo F,Leiguarda R

更新日期：1992-02-01 00:00:00

abstract：:Deprenyl, a selective inhibitor of monoamine oxidase, type B, which is free of the "tyramine effect," may ameliorate symptom fluctuations in advanced Parkinson's disease (PD). We randomized 96 patients with marked symptom fluctuations at three centers to receive either deprenyl 5 mg b.i.d. or placebo in parallel fashi...

journal_title：Clinical neuropharmacology

authors： Golbe LI,Lieberman AN,Muenter MD,Ahlskog JE,Gopinathan G,Neophytides AN,Foo SH,Duvoisin RC

更新日期：1988-02-01 00:00:00

abstract：BACKGROUND:Serotonin syndrome (SS) is a potentially life-threatening condition that can be caused by use of proserotonergic drugs. Several studies have reported that combined administration of various medications may induce SS. We report a case of SS in a patient who was being treated with dopaminergic and noradrenergi...

journal_title：Clinical neuropharmacology

authors： Jeon DG,Kim YW,Kim NY,Park JH

更新日期：2017-07-01 00:00:00

abstract：:The anticonvulsant potential of lamotrigine (LTG) has been extensively assessed in open and double-blind clinical trials including patients with different types of epilepsy. In this review, the neurophysiologic and neuropsychologic profile of LTG is discussed. The electroencephalographic (EEG) findings reveal that the...

journal_title：Clinical neuropharmacology

authors： Marciani MG,Spanedda F,Mattia D

更新日期：1999-05-01 00:00:00

abstract：:The treatment of obesity remains a puzzling challenge because long-term maintenance of weight loss--one of the most suitable goals--is rarely achieved with conventional methods. Among the theoretical measures able to maintain a permanent and bearable constraint to obtain the maintenance of weight loss is long-term (li...

journal_title：Clinical neuropharmacology

authors： Guy-Grand BJ

更新日期：1988-01-01 00:00:00

abstract：OBJECTIVES:We investigated the effects of age on the association between early and eventual responses to paroxetine treatment in patients with major depressive disorder (MDD). METHODS:Eighty-nine patients with MDD were administered paroxetine and completed the 6-week protocol. On the basis of our previous study, we de...

journal_title：Clinical neuropharmacology

authors： Tomita T,Sato Y,Nakagami T,Tsuchimine S,Kaneda A,Kaneko S,Nakamura K,Yasui-Furukori N

更新日期：2015-01-01 00:00:00

abstract：:Seven of 63 children (11%) treated with clobazam (CLB) for refractory epilepsy developed a severe behavior disorder. This disorder was characterized by aggressive agitation, self injurious behavior, insomnia, and incessant motor activity occurring between 10 and 55 days after initiation of drug therapy. The affected c...

journal_title：Clinical neuropharmacology

authors： Sheth RD,Goulden KJ,Ronen GM

更新日期：1994-08-01 00:00:00

abstract：OBJECTIVE:A multicenter open-label clinical trial was conducted to evaluate the clinical usefulness of topiramate (TPM) as primary or adjunctive therapy for infantile spasms in the postmarketing period in China. METHODS:Thirty-four centers participated in the trial. Patients included in the study had 1 or more seizure...

journal_title：Clinical neuropharmacology

authors： Zou LP,Lin Q,Qin J,Cai FC,Liu ZS,Mix E,Topiramate Study Group.

更新日期：2008-03-01 00:00:00

abstract：:To evaluate the efficacy and safety of gabapentin in the treatment of muscle cramps, we engaged an open-label trial with a group of 30 patients with frequent (> 5 cramps/week), stable, long-lasting cramps, associated with different diseases. Gabapentin was effective in reducing the frequency and severity of muscle cra...

journal_title：Clinical neuropharmacology

authors： Serrao M,Rossi P,Cardinali P,Valente G,Parisi L,Pierelli F

更新日期：2000-01-01 00:00:00

abstract：:The purpose of this paper is to add to the growing number of reports about kleptomania occurring in relation to brain injury as well as to present the authors' findings regarding treatment strategies. The authors present two case reports of patients who developed the new onset of kleptomania after closed head trauma. ...

journal_title：Clinical neuropharmacology

authors： Aizer A,Lowengrub K,Dannon PN

更新日期：2004-09-01 00:00:00

abstract：:We describe a 78-year-old gentleman who, following bilateral above-knee amputations, developed symptoms of restless legs syndrome in the absent portions of his lower extremities. These symptoms improved with dopamine agonist therapy. In addition, he later developed parkinsonism with prominent rest tremor on metoclopra...

journal_title：Clinical neuropharmacology

authors： Hanna PA,Kumar S,Walters AS

更新日期：2004-03-01 00:00:00

abstract：:Data on a twice-daily dosage schedule with moclobemide in the treatment of depression is limited. In this study, moclobemide 150 mg twice daily (b.i.d.) was compared to two different three-times-daily (t.i.d.) regimens with total daily dosages of 300 and 450 mg, respectively, over a 6-week period. The study was random...

journal_title：Clinical neuropharmacology

authors： Gagiano CA,Hart GA,Bodemer W,Schall R

更新日期：1994-01-01 00:00:00

abstract：:The present study was carried out in order to verify whether, in benzodiazepine-medicated healthy volunteers, oxiracetam retained the properties already observed after administration in normal volunteers. In a cross-over study, 12 volunteers, medicated the night before with 5 mg diazepam, were i.v. treated with 1 g ox...

journal_title：Clinical neuropharmacology

authors： Giaquinto S,Nolfe G,Vitali S

更新日期：1986-01-01 00:00:00

abstract：:Dehydroepiandrosterone (DHEA) is an important neurosteroid and has demonstrated efficacy in the improvement of mood and energy. The authors previously reported the efficacy of DHEA augmentation in the management of negative, depressive, and anxiety symptoms of schizophrenia. To characterize further the effects of DHEA...

journal_title：Clinical neuropharmacology

authors： Strous RD,Maayan R,Kotler M,Weizman A

更新日期：2005-11-01 00:00:00